Program
SYS6023
A development code.
Its studies are mostly in Breast Neoplasms, led by CSPC Pharmaceutical Group.
Furthest: phase 2, since May 13, 20262 company-led studies, 2 open or runningNext primary completion: Nov 30, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CSPC Pharmaceutical Group | 22 open or running | phase 2since May 13, 2026 | Jul 14, 2025 | Nov 30, 2027phase 2 · NCT07597629 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 14, 2025First study: phase 1 study in Advanced Solid TumorFirst studyNCT07110883 · 400 planned · China
- May 13, 2026Phase 2 study in Advanced Breast CancerPhase 2 reachedNCT07597629 · 36 planned · China
Ahead
- Nov 30, 2027Primary completion: phase 2 study in Advanced Breast CancerNCT07597629
TargetBeta
ERBB3 →read by rule
“SYS6023 is a novel antibody-drug conjugate (ADC) targeting HER3, administered via intravenous infusion.”study text, by rule · the study
Other programs on ERBB3
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| izalontamab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 55 |
| patritumab deruxtecan | Merck | phase 3 | 17 |
| beruzatatug pelitecanrule | MediLink Therapeutics (Suzhou) | phase 3 | 9 |
| ruzaltatug rezetecan | Jiangsu HengRui Medicine | phase 3 | 8 |
| JSKN016rule | Alphamab Oncology | phase 3 | 5 |
| Anti-HER3/Anti-MUC1 Bispecific Antibody-drug Conjugate DM002rule | xadcera-biopharmaceutical-suzhou-co-ltd | phase 2 | 1 |
| Anti-HER3/Exatecan Antibody-drug Conjugate ENV-501rule | hummingbird-bioscience | phase 2 | 1 |
| Anti-EGFR/Anti-HER3 Bispecific Antibody-drug Conjugate AVZO-1418rule | avenzo-therapeutics-inc | phase 2 | 1 |
| KHN922rule | Chengdu Kanghong Pharmaceutical Group | phase 2 | 1 |
| CS5007rule | CStone Pharmaceuticals | phase 1 | 1 |
| JSKN016HCrule | Alphamab Oncology | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07597629Advanced Breast Cancer · China | 2 | Recruiting | Nov 30, 2027 | 36 |
| NCT07110883Advanced Solid Tumor · China | 1 | Recruiting | Oct 31, 2026 | 400 |
How it is read
Names in the registry
- “SYS6023”, 2 entries
Codes read as this program: SYS6023.
Conditions, from the studies’ own filings
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.